Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Graft Polymer (UK) PLC ( (GB:SVNS) ).
Solvonis Therapeutics PLC has reported significant progress in the first half of 2025, highlighted by the acquisition of Awakn Life Sciences, which has expanded its pipeline and strengthened its position as a CNS-focused biopharmaceutical platform. The company is advancing its R&D programs, including SVN-001 for Alcohol Use Disorder and SVN-SDN-014 for PTSD, and is well-positioned to deliver value for patients and shareholders. Financially, Solvonis reported a loss before taxation of £1,621,000, but increased its cash and cash equivalents to £1,719,000, reflecting a strategic focus on growth and innovation.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics PLC is a clinical-stage biopharmaceutical company based in London, focusing on developing novel treatments for addiction and mental health disorders. The company is listed on the London Stock Exchange and is advancing a pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions, including Alcohol Use Disorder and Post-Traumatic Stress Disorder.
Average Trading Volume: 89,375,685
Technical Sentiment Signal: Buy
Current Market Cap: £23.05M
Learn more about SVNS stock on TipRanks’ Stock Analysis page.